People · Operator
Named in public records as an officer, director or promoter · active 2009–2009 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Elite Pharmaceuticals Inc /Nv/ | — | Pharmaceuticals | Pre-Seed | $3.3M | $23.4M | 2009 |
Mark Gittelman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark Gittelman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert J. Levenson | 1 | 2 |
| Carter Ward | 1 | 2 |
| Jerry Treppel | 1 | 1 |
| Chris Dick | 1 | 1 |
| Jeffrey Whitnell | 1 | 1 |
| Ashok Nigalaye | 1 | 1 |
| Jeenarine Narine | 1 | 1 |
| Nasrat Hakim | 1 | 1 |
| Douglas Plassche | 1 | 1 |
| Davis Caskey | 1 | 1 |
| Barry Dash | 1 | 1 |
| Eugene Pfeifer | 1 | 1 |
| Melvin Van Woert | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.